ELANE and pulmonary emphysema: A somewhat missed opportunity to verify the protective effect of augmentation therapy is the lack of definitive evidence that biomarkers of connective tissue degradation thought to be central to the development of emphysema, such as desmosines in plasma or more specific peptides derived from the microenviromental activity of neutrophil elastase, decline after initiation of intravenous augmentation therapy.